ArticleCancer2012

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.

Seth M Pollack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.